H. Sung, J. Ferlay, R.L. Siegel, et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clinicians 71, 209–249 (2021)

Article  Google Scholar 

E. Morgan, M. Arnold, M.C. Camargo, et al., The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: a population-based modelling study. EClinicalMedicine 47, 101404 (2022)

Article  PubMed  PubMed Central  Google Scholar 

T. Sano, D.G. Coit, H.H. Kim, F. Roviello, et al., Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer. 20(2), 217–225 (2017)

Article  PubMed  Google Scholar 

American Cancer Society, Cancer Facts & Figures 2021 (American Cancer Society, 2021)

X. Zhang, H. Liang, Z. Li, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. (2021)

J.A. Ajani, T.A. D’Amico, D.J. Bentrem, et al., Gastric cancer, version 2.2022, NCCN Clinical Practice Guidelines in Oncology J. Natl. Compr. Cancer Netw. 20(2), 167–192 (2022)

D. Cunningham, W.H. Allum, S.P. Stenning, J.N. Thompson, et al., Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355(1), 11–20 (2006)

S.E. Al-Batran, R.D. Hofheinz, C. Pauligk, et al., Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial Lancet Oncol. 17(12), 1697–1708 (2016)

Y.Y. Janjigian, K. Shitara, M. Moehler, et al., First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27–40 (2021)

Article  CAS  PubMed  PubMed Central  Google Scholar 

N. Boku, M.H. Ryu, K. Kato, et al., Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann. Oncol. 30, 250–258 (2019)

Article  CAS  PubMed  Google Scholar 

T. Liu, Y. Bai, X. Lin, et al., First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: checkMate 649 Chinese subgroup analysis. Int. J. Cancer 152, 749–760 (2022)

Article  PubMed  PubMed Central  Google Scholar 

R.H. Xu, D.Y. Oh, K. Kato, et al., LBA80 Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis results of the RATIONALE-305 study. Ann. Oncol. 34, S1320-S1 (2023)

Google Scholar 

S.-Q. Yuan, R.-C. Nie, Y. Jin, et al., Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nature Med. 30(2), 552–559 (2024)

Article  CAS  PubMed  Google Scholar 

H. Jiang, X. Yu, N. Li, et al., Efficacy and Safety of Neoadjuvant Sintilimab, Oxaliplatin and Capecitabine in Patients with Locally Advanced, Resectable Gastric or Gastroesophageal Junction Adenocarcinoma: Early Results of a Phase 2 Study (2022), p. e003635. https://doi.org/10.1136/jitc-2021-003635

Book  Google Scholar 

S.A.-O. Li, W. Yu, F. Xie, et al., Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer Nat. Commun. 14(1), 8 (2023)

W.A.-O. Sun, N. Veeramachaneni, R. Al-Rajabi, et al., A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma Cancer Med. 12(15), 16098–16107 (2023)

J.P.T. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li, M.J. Page, V.A. Welch (ed.), Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (Updated August 2023) (Cochrane, 2023). www.training.cochrane.org/handbook

D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339 (2009)

K. Slim, E. Nini, D. Forestier, F. Kwiatkowski, Y. Panis, J. Chipponi, Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J. Surg. 73, 712–716 (2003)

Article  PubMed  Google Scholar 

A.C.S. Jonathan, S. Jelena, J.P. Matthew, et al., RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019)

Google Scholar 

Y.-J. Bang, Y.-K. Kang, D.V. Catenacci, et al., Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer 22, 828–837 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

H. Guo, P. Ding, C. Sun, et al., Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: a single-arm, open-label, phase II trial. Front. Oncol. 12, 927781 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Y.-K. Kang, L.-T. Chen, M.-H. Ryu, et al., Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 234–247 (2022)

Article  CAS  PubMed  Google Scholar 

A. Kawazoe, K. Yamaguchi, H. Yasui, et al., Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: cohort 1 data from the KEYNOTE-659 phase IIb study. Eur. J. Cancer 129, 97–106 (2020)

Article  CAS  PubMed  Google Scholar 

C.-K. Lee, J.B. Lee, S.J. Park, et al., Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study. Gastric Cancer 27, 118–130 (2023)

Article  PubMed  Google Scholar 

C.-K. Lee, S.Y. Rha, H.S. Kim, et al., A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Nat. Commun. 13 (2022)

S. Li, J. Bao, X. Li, et al., Multicenter phase I dose escalation and expansion study of pyrotinib in combination with camrelizumab and chemotherapy as first-line treatment for HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. EClinicalMedicine 66, 102314 (2023)

Article  PubMed  PubMed Central  Google Scholar 

G.A. Manji, S. Lee, A. Del Portillo, et al., Chemotherapy and immune checkpoint blockade for gastric and gastroesophageal junction adenocarcinoma. JAMA Oncol. 9, 1702 (2023)

Article  PubMed  PubMed Central  Google Scholar 

S.Y. Rha, D.-Y. Oh, P. Yañez, et al., Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181–1195 (2023)

Article  CAS  PubMed  Google Scholar 

K. Shitara, J.A. Ajani, M. Moehler, et al., Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603, 942–948 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

K. Shitara, E. Van Cutsem, Y.-J. Bang, et al., Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer. JAMA Oncol. 6, 1571 (2020)

Article  PubMed  Google Scholar 

A. Stein, L. Paschold, J. Tintelnot, et al., Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-Positive esophagogastric adenocarcinoma. JAMA Oncol. 8(8), 1150–1158 (2022)

PubMed  PubMed Central  Google Scholar 

W. Sun, N. Veeramachaneni, R. Al-Rajabi, et al., A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma. Cancer Med. 12, 16098–16107 (2023)

Article  CAS  PubMed  PubMed Central  Google Scholar 

J. Xu, H. Jiang, Y. Pan, et al., Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer. Jama 330, 2064 (2023)

Article  PubMed  PubMed Central  Google Scholar 

J. Xu, N. Xu, Y. Bai, et al., Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial. OncoImmunology. 10(1), 1864908 (2020)

Article  PubMed  PubMed Central  Google Scholar 

J.W. Shi, Y. Zhou, S. Wu Clinical efficacy and safety of adjuvant immunotherapy (Tislelizumab) plus chemotherapy vs. adjuvant chemotherapy alone in lymph node-positive patients with gastric cancer after D2 radical resection: a prospective, 2-arm, phase II study Eur. Rev. Med. Pharmacol. Sci. 27(21), 10472–10480 (2023)

Y. Song, N. Li, Q. Li, et al., HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. J. Immunother. Cancer. e001279 (2020). https://doi.org/10.1136/jitc-2020-001279

K. Shitara, S.Y. Rha, L.S. Wyrwicz, et al., Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 25(2), 212–224 (2024). https://doi.org/10.1016/S1470-2045(23)00541-7

Article  CAS  PubMed  Google Scholar 

J.E. Rogers, L. Xiao, A. Trail, M. Blum Murphy, M. Palmer, J.A. Ajani Nivolumab in combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for refractory advanced gastroesophageal cancer Oncology. 98(5), 289–294 (2020)

X. Zhang, C. Zhang, H. Hou, et al. Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: a single-centre retrospective study Transl. Oncol. 31, 101657 (2023)

G. Mouillet, E. Monnet, B. Milleron, M. Puyraveau, et al. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials J. Thorac. Oncol. 7(5), 841–849 (2012)

N.A. Waser, A. Adam, B. Schweikert, et al., 1243P Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): systematic literature review and meta-analysis. Ann. Oncol. 31, S806 (2020)

Article  Google Scholar 

J.S. Deutsch, A. Cimino-Mathews, E. Thompson, et al., Association between Pathologic Response and Survival after Neoadjuvant Therapy in Lung Cancer. https://doi.org/10.1038/s41591-023-02660-6

Y. Fujiwara, N. Horita, E. Adib, et al., Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials. Lancet Oncol. 25(1), 62–75 (2024).